MDxHealth SA
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsMDxHealth SA is a Belgian molecular diagnostics company providing prostate cancer and other urologic tests, listed on Nasdaq.
What they do
MDxHealth develops and commercializes epigenetic and exosome-based diagnostic tests. Its product portfolio includes Confirm mdx, Select mdx, Resolve mdx, and ExoDx Prostate Intelliscore (EPI), targeting prostate cancer diagnosis and management. The company operates primarily in the U.S. through its subsidiary MDxHealth, Inc., with laboratory services as the main revenue source.
Revenue drivers
- Confirm mdx — A post-biopsy epigenetic test used to determine if a repeat biopsy is needed for prostate cancer patients; it is a primary commercial product.
- ExoDx Prostate Intelliscore (EPI) — A urine-based exosome test designed to assess prostate cancer risk and reduce unnecessary biopsies; key growth product.
- Select mdx / Resolve mdx — Other urologic cancer tests in the portfolio that contribute to revenue, though smaller than Confirm mdx and EPI.
Recent performance
The 20-F does not provide detailed financial results in the excerpt. As of December 31, 2025, the company had 51,364,520 ordinary shares outstanding. No revenue, profit, or cash flow figures are provided in the available text. The company continues to trade on Nasdaq under the symbol MDXH after delisting from Euronext Brussels in December 2023.
Strategy
The company focuses on expanding its urologic diagnostic portfolio and commercializing its tests in the U.S. market. It emphasizes its proprietary epigenetic and exosome technologies. Management prioritizes increasing test volume and market penetration for existing products while maintaining operational efficiency. No specific R&D or M&A priorities are disclosed in the excerpt.
Risks
- Concentration in urologic diagnostics — Revenue heavily depends on a few tests; adverse changes in reimbursement or clinical adoption could hurt results.
- Reimbursement and payer coverage — Laboratory tests face ongoing risk of coverage denials or lower reimbursement rates from Medicare and private payers.
- Competition — The prostate cancer diagnostic market is competitive with other molecular tests and emerging technologies.
- Operational execution — The company is relatively small and may face challenges in scaling commercial operations and managing growth.
Outlook
Management's forward-looking statements include increasing adoption of its diagnostic tests and expanding its commercial footprint. The company's transition to a pure Nasdaq listing is complete, providing access to U.S. capital markets. No specific financial guidance is provided in the excerpt.